Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brofaromine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Brofaromine is a small molecule drug that acts as a selective, reversible inhibitor of monoamine oxidase A (MAO-A), also known as a RIMA (reversible inhibitor of monoamine oxidase A). It was developed by Ciba-Geigy (now part of Novartis) for the treatment of depression and anxiety disorders. In addition to its MAO-A inhibitory activity, brofaromine also inhibits serotonin reuptake, giving it dual pharmacological effects that were thought to offer advantages in treating depressive disorders with fewer anticholinergic side effects compared to tricyclic antidepressants. Despite promising clinical trial results showing efficacy comparable to tricyclic antidepressants and standard MAOIs, development was discontinued before market approval. Brofaromine was also investigated for post-traumatic stress disorder (PTSD)[2][3][5][6][7][8].
- Brand names
- ConsonarConsonev
- Other names
- brofarominebrofaremine63638-91-5Brofaromina
02
Targets
SERT (Sodium-dependent serotonin transporter)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on Brofaromine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brofaromine.